LA HAP Bulletin for 3-7-19

SYMFI, SYMFI LO, and CIMDUO added to LA HAP formulary

Effective 3/1/19, LA HAP has added SYMFI (efavirenz [600 mg]/tenofovir disproxil/lamivudine), SYMFI LO (efavirenz [400 mg]/tenofovir disproxil/lamivudine) and CIMDUO (tenofovir disoproxil fumarate/lamivudine) to the LA HAP formulary for uninsured clients. Insured clients may access these medications provided they are covered by their primary insurer’s formulary.

2019 Federal Poverty Income Guidelines now in use

Following Louisiana Medicaid’s adoption of the 2019 Federal Poverty Income Guidelines (FPIG) in March, LA HAP is now assessing program eligibility based on these guidelines. They can be found here and on our homepage.